Biotechnologies in haematological malignancies.

R. Foà, G. Reato, A. Guarini

Research output: Contribution to journalArticle

Abstract

The last fifteen years have witnessed impressive changes in our approach to patients with different haematological malignancies. These have largely stemmed from the continuous development of biotechnologies and from their progressive implementation in the clinical setting. In this brief review, we will highlight some of the areas (diagnosis, follow-up and treatment) in which biotechnologies have had an objective impact and will also underline how a close biologico-clinical integration, unparalleled in all other fields of oncology, is today mandatory for an up-to-date management of haematological malignancies.

Original languageEnglish
Pages (from-to)54-58
Number of pages5
JournalFORUM - Trends in Experimental and Clinical Medicine
Volume9
Issue number3 Suppl 3
Publication statusPublished - Jul 1999

Fingerprint

Hematologic Neoplasms
Biotechnology
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Biotechnologies in haematological malignancies. / Foà, R.; Reato, G.; Guarini, A.

In: FORUM - Trends in Experimental and Clinical Medicine, Vol. 9, No. 3 Suppl 3, 07.1999, p. 54-58.

Research output: Contribution to journalArticle

@article{5d8e09bad4c448d29662d55c4092205e,
title = "Biotechnologies in haematological malignancies.",
abstract = "The last fifteen years have witnessed impressive changes in our approach to patients with different haematological malignancies. These have largely stemmed from the continuous development of biotechnologies and from their progressive implementation in the clinical setting. In this brief review, we will highlight some of the areas (diagnosis, follow-up and treatment) in which biotechnologies have had an objective impact and will also underline how a close biologico-clinical integration, unparalleled in all other fields of oncology, is today mandatory for an up-to-date management of haematological malignancies.",
author = "R. Fo{\`a} and G. Reato and A. Guarini",
year = "1999",
month = "7",
language = "English",
volume = "9",
pages = "54--58",
journal = "FORUM - Trends in Experimental and Clinical Medicine",
issn = "1121-8142",
publisher = "Scuola superiore di oncologia e scienze biomediche",
number = "3 Suppl 3",

}

TY - JOUR

T1 - Biotechnologies in haematological malignancies.

AU - Foà, R.

AU - Reato, G.

AU - Guarini, A.

PY - 1999/7

Y1 - 1999/7

N2 - The last fifteen years have witnessed impressive changes in our approach to patients with different haematological malignancies. These have largely stemmed from the continuous development of biotechnologies and from their progressive implementation in the clinical setting. In this brief review, we will highlight some of the areas (diagnosis, follow-up and treatment) in which biotechnologies have had an objective impact and will also underline how a close biologico-clinical integration, unparalleled in all other fields of oncology, is today mandatory for an up-to-date management of haematological malignancies.

AB - The last fifteen years have witnessed impressive changes in our approach to patients with different haematological malignancies. These have largely stemmed from the continuous development of biotechnologies and from their progressive implementation in the clinical setting. In this brief review, we will highlight some of the areas (diagnosis, follow-up and treatment) in which biotechnologies have had an objective impact and will also underline how a close biologico-clinical integration, unparalleled in all other fields of oncology, is today mandatory for an up-to-date management of haematological malignancies.

UR - http://www.scopus.com/inward/record.url?scp=0033155226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033155226&partnerID=8YFLogxK

M3 - Article

C2 - 10607847

AN - SCOPUS:0033155226

VL - 9

SP - 54

EP - 58

JO - FORUM - Trends in Experimental and Clinical Medicine

JF - FORUM - Trends in Experimental and Clinical Medicine

SN - 1121-8142

IS - 3 Suppl 3

ER -